Drug Trial Radar · NCT03745287
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
63
Actual
Start
Nov 27, 2018
Primary completion
Jul 7, 2025
Study completion Jul 7, 2025
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- Collaborators
- CRISPR Therapeutics
- First posted
- Nov 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in participants with severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using CTX001.
Conditions
- Sickle Cell Disease
- Hematological Diseases
- Hemoglobinopathies
Interventions
Exa-celBiological
Administered by IV infusion following myeloablative conditioning with busulfan.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Have Not Experienced Any Severe Vaso-occlusive Crisis (VOC) for at Least 12 Consecutive Months (VF12) After Exa-cel InfusionTime frame: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
- Percentage of Participants Who Achieve Neutrophil EngraftmentTime frame: Up to 24 months post exa-cel infusion.
- Time to Neutrophil Engraftment for Participants Who Achieve Neutrophil EngraftmentTime frame: Up to 24 months post exa-cel infusion.
- Time to Platelet Engraftment for Participants Who Achieve Platelet EngraftmentTime frame: From Exa-cel infusion up to 2 years after exa-cel infusion
- Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From receiving exa-cel infusion up to 2 years
- Transplant-related Mortality (TRM) Within 100 Days After Exa-cel InfusionTime frame: Within 100 days after exa-cel infusion
- Transplant-related Mortality Within 12 Months Post Exa-cel InfusionTime frame: Within 12 months post exa-cel infusion
- All-cause MortalityTime frame: From exa-cel infusion up to 2 years
Locations
17 sites in 7 countries. Site status is shown where the registry gives one.
Lucile Packard Children's Hospital of Stanford University
Palo Alto, California
Ann & Robert Lurie Children's Hospital of Chicago
Chicago, Illinois
University of Illinois at Chicago Hospitals and Health Systems
Chicago, Illinois
Columbia University Medical Center (21+ years)
New York, New York
Columbia University Medical Center (≤21 years)
New York, New York
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
St. Jude Children's Research Hospital
Memphis, Tennessee
The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers
Nashville, Tennessee
Methodist Children's Hospital/Texas Transplant Institute
San Antonio, Texas
Hopital Universitaire des Enfants Reine Fabiola (HUDERF)
Brussels, Belgium
The Hospital for Sick Children
Toronto, Canada
Hopital Necker Enfants Malades
Paris, France
University Hospital Duesseldorf
Düsseldorf, Germany
Regensburg University Hospital, Clinic and Polyclinic for Paediatric and Adolescent Medicine, Paediatric Haemotology, Oncology and Stem Cell Transplantation
Regensburg, Germany
Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS
Rome, Italy
Imperial College Healthcare NHS Trust, Hammersmith Hospital
London, United Kingdom
Royal London and St Bartholomew's Hospital, Pathology and Pharmacy Building
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.